PDF
(Download)
|
- Pelargonium sidoides
- EPs 7630
- Acute BronchitisChildren and Adolescents
| Date:
06-15-2012 | HC# 041236-450
|
Re: An Extract of Pelargonium sidoides Root (EPs 7630) Is Safe and Effective in Children and Adolescents with Acute Bronchitis
Kamin
W, Ilyenko LI, Malek FA, Kieser M. Treatment of acute bronchitis with EPs 7630:
Randomized, controlled trial in children and adolescents. Pediatr Int. 2012 Apr;54(2):219-226.
Acute
bronchitis is a common childhood illness. Although 95% of the cases are caused
by viruses, about one-third of patients are prescribed antibiotics. Studies
have shown that antibiotic therapy is mostly ineffective in acute bronchitis,
unless the pathogen is of bacterial origin and known by lab test. A therapeutic
alternative in the first-line treatment of acute bronchitis is EPs 7630 (the
active ingredient of the product Umckaloabo®; ISO Arzneimittel;
Ettlingen, Germany), which has been approved in Germany for use in adults and
in children aged 1 year and older. EPs 7630 is an herbal drug preparation derived
from the roots of Pelargonium sidoides
(1:8-10); extraction solvent: ethanol, 11% (w/w). These authors conducted a
randomized, double-blind, placebo-controlled clinical trial to demonstrate the
efficacy and tolerability of EPs 7630 in children and adolescents suffering
from acute bronchitis.
The
pharmacological activities of EPs 7630 and its components, which include
antibacterial potencies and immunomodulatory capabilities, have been
demonstrated in vitro. The immunomodulatory activities are mainly mediated by
the release of tumor necrosis factor-α and nitric oxides, the stimulation of
interferon-β, and the increase in natural killer cell activity.1-4
This
study was conducted between March 2006 and May 2006 in 11 Russian centers.
Patients meeting the inclusion criteria were randomly allocated to 1 of 2
treatment groups. Following a baseline examination and subjective evaluations,
the patients were scheduled for follow-up examinations on days 3-5 (visit 2)
and day 7 (visit 3).
To
be included, the patients had to be aged 1-18 years; suffering from acute
bronchitis with symptoms starting ≤48 hours before inclusion in the study; and have
a total score of bronchitis-specific symptoms (BSS) ≥5 points at the time of
screening.
A
total of 220 patients were randomized to receive EPs 7630 (n=111) or placebo
(n=109) as follows: 10 drops 3 times daily for patients aged 1-6 years; 20
drops 3 times daily for patients aged >6 to 12 years; or 30 drops 3 times
daily for patients aged >12 to 18 years for 7 consecutive days.
No
significant differences were noted at baseline between the groups for
demographic and anthropometric data. Concomitant medication was taken by 6.3% of
patients in the EPs 7630 group and 10.1% in the placebo group. Acetaminophen
use was allowed and did not differ between groups. Antibiotics were taken by 5
patients in the EPs 7630 group and 3 patients in the placebo group.
The
primary efficacy variable was the change in the BSS total score from day 0 to
day 7. The BSS total score comprised the 3 items "coughing,"
"pulmonary rales at auscultation" (also known as "crackles";
the clicking, rattling, or crackling noises that may be made by one or both
lungs), and "dyspnea" (difficult breathing; shortness of breath). At
each visit, those symptoms were scored according to a 5-point verbal rating
scale from 0 ("not present") to 4 ("very severe").
From
baseline to day 7, the mean BSS total score decreased by 4.4 ± 1.6 points in
the EPs 7630 group compared with 2.9 ± 1.4 points in the placebo group.
A
continuous decrease in the mean BSS total score between baseline and day 7 was
observed in both groups, but scores were significantly better with EPs 7630
than placebo after 3-5 days and 7 days: EPs 7630 vs. placebo ― day 0: 6.0 ± 1.6
vs. 5.8 ± 1.3; days 3-5: 3.6 ± 1.4 vs. 4.3 ± 1.4; day 7: 1.6 ± 1.4 vs. 2.9 ± 1.4
(P<0.0001 for days 3-5 and day 7, respectively).
For
the individual symptoms "coughing" and "pulmonary rales at auscultation,"
the mean decrease in BSS between day 0 and day 7 was more pronounced in the EPs
7630 group compared with the placebo group (P<0.0001). "Dyspnea"
showed a nonsignificant advantage for EPs 7630.
Regarding
general symptoms, "lack of appetite" was significantly improved in
the EPs 7630 group at day 7 (P=0.0003).
Amongst
other secondary efficacy variables were the response rates defined as a BSS
total score of <3 points at day 7 (criterion 1); a decrease in the BSS total
score by at least 4 points from day 0 to day 7 (criterion 2); and a BSS total
score <3 at day 7 combined with a decrease in the BSS total score by at
least 4 points from day 0 to day 7 (criterion 3).
Response
rates at day 7 were considerably higher in the EPs 7630 group compared with the
placebo group. For all 3 response criteria, a statistically significant
difference was observed for the EPs 7630 group (P<0.0001 for each).
The
treatment effect occurred significantly earlier in the EPs 7630 group compared
with the placebo group (P<0.0001).
Evaluation
of the treatment outcome by the investigator and the satisfaction of patients
with the treatment were each significantly better in the EPs 7630 group
compared with the placebo group (P<0.0001 for both).
Three
adverse events were observed in 2 of the 111 patients in the EPs 7630 group,
but a causal relationship was excluded in all 3 cases. Clinical laboratory
parameters showed only marginal group differences.
These
results support the efficacy, tolerability, and safety of the herbal drug
preparation EPs 7630 in children and adolescents aged 1-18 years suffering from
acute bronchitis. This confirms a previously published observational study in
children ages 0-12 years.5
According
to the authors, the treatment benefit was most
pronounced for the symptoms "coughing" and "rales at
auscultation," which could be explained by the improvement of ciliary
beating as found in vitro.6 They suggest that this could be an important mode of action independent
of antibacterial activity as most episodes of acute bronchitis are caused by viruses.
The
authors point out that even in diseases requiring antimicrobial therapy,
initial treatment with EPs 7630 could "bridge the time between
presentation of the patient and the final decision on an appropriate antibiosis,
thus reducing the risk of uncritical antibiotic treatment."
A
previous systematic review of 6 clinical trials on the use of EPs 7630 by
patients with bronchitis concluded there is "encouraging evidence from currently available data that P. sidoides is effective compared to
placebo for patients with acute bronchitis."7
—Shari
Henson
References
1Kayser O, Kolodziej H,
Kiderlen AF. Immunomodulatory principles of Pelargonium sidoides. Phytother
Res. 2001;15(2):122-126.
2Kolodziej H.
Fascinating metabolic pools of Pelargonium sidoides and Pelargonium
reniforme, traditional and phytomedicinal sources of the herbal medicine
Umckaloabo®. Phytomedicine. 2007;14(Suppl 1):9-17.
3Kolodziej H, Kayser O,
Radtke OA, Kiderlen AF. Pharmacological profile of extracts of Pelargonium
sidoides and their constituents. Phytomedicine. 2003;10(Suppl 4):18-24.
4Kolodziej H, Kiderlen
AF. In vitro evaluation of antibacterial and immunomodulatory activities of Pelargonium
reniforme, Pelargonium sidoides and the related herbal drug preparation EPs®
7630. Phytomedicine. 2007;14(Suppl
1):18-26.
5Minigh J. Pelargonium sidoides as a treatment for
acute bronchitis in children. HerbClip.
February 15, 2008 (No. 050273-346). Austin, TX: American Botanical Council.
Review of Treatment effect and safety of EPs® 7630-solution in acute
bronchitis in childhood: Report of a multicentre observational study by
Haidvogl M, Heger M. Phytomedicine.
2007;14(Suppl 1):60-64.
6Neugebauer P, Mickenhagen A, Siefer O, Walger M. A new approach to
pharmacological effects on ciliary beat frequency in cell cultures – exemplary
measurements under Pelargonium sidoides extract (EPs 7630). Phytomedicine.
2005;12(1-2):46-51.
7Agbabiaka TB, Guo R,
Ernst E. Pelargonium sidoides for
acute bronchitis: a systematic review and meta-analysis. Phytomedicine.
May 2008;15(5):378-385.
|